Block 3 Drugs

Front 1

Cyclophosphamide

Back 1

Alkylating agent

Front 2

Ifosfamide

Back 2

Alkylating agent

Front 3

Bendamustine

Back 3

Alkylating agent

Front 4

Busulfan

Back 4

Alkylating agent

Front 5

Chlorambucil

Back 5

Alkylating agent

Front 6

Carmustine

Back 6

Alkylating agent

Front 7

Lomustine

Back 7

Alkylating agent

Front 8

Mechlorethamine

Back 8

Alkylating agent

Front 9

Melphalan

Back 9

Alkylating agent

Front 10

Streptozocin

Back 10

Alkylating agent

Front 11

Thiotepa

Back 11

Alkylating agent

Front 12

Dacarbazine

Back 12

Alkylating agent

Front 13

Temozolomide

Back 13

Alkylating agent

Front 14

Procarbazine

Back 14

Alkylating agent

Front 15

Cisplatin

Back 15

DNA binding agent

Front 16

Carboplatin

Back 16

DNA binding agent

Front 17

Oxaliplatin

Back 17

DNA binding agent

Front 18

Cytarabine

Back 18

Antimetabolite

Front 19

Methotrexate

Back 19

Antimetabolite

Front 20

Premetrexed

Back 20

Antimetabolite

Front 21

5-fluorouracil

Back 21

Antimetabolite

Front 22

Capecitabine

Back 22

Antimetabolite

Front 23

Cladribine

Back 23

Antimetabolite

Front 24

Fludarabine

Back 24

Antimetabolite

Front 25

Gemcitabine

Back 25

Antimetabolite

Front 26

6-mercaptopurine

Back 26

Antimetabolite

Front 27

Pentostatin

Back 27

Antimetabolite

Front 28

6-thioguanine

Back 28

Antimetabolite

Front 29

Doxorubicin

Back 29

Antitumor antibiotic

Front 30

Daunorubicin

Back 30

Antitumor antibiotic

Front 31

Epirubicin

Back 31

Antitumor antibiotic

Front 32

Idarubicin

Back 32

`Antitumor antibiotic

Front 33

Mitoxantrone

Back 33

Antitumor antibiotic

Front 34

Actinomycin D

Back 34

Antitumor antibiotic

Front 35

Bleomycin

Back 35

Antitumor antibiotic

Front 36

Irinotecan

Back 36

Topoisomerase I inihibitor

Front 37

Topotecan

Back 37

Topoisomerase I inhibitor

Front 38

Etopside

Back 38

Topoisomerase II inhibitor

Front 39

Teniposide

Back 39

Topoisomerase II inhibitor

Front 40

Vincristine

Back 40

Mitotic inhibitors

Front 41

Vinblastine

Back 41

Mitotic inhibitors

Front 42

Paclitaxel

Back 42

Mitotic inhibitors

Front 43

Docetaxel

Back 43

Mitotic inhibitors

Front 44

Ixabepilone

Back 44

Mitotic inhibitors

Front 45

Erlotinib

Back 45

Signal transduction inhibitors

Front 46

Imatinib

Back 46

Signal transduction inhibitors

Front 47

Dasatinib

Back 47

Signal transduction inhibitors

Front 48

Nilotinib

Back 48

Signal transduction inhibitors

Front 49

Sunitinib

Back 49

Signal transduction inhibitors

Front 50

Sorafenib

Back 50

Signal transduction inhibitors

Front 51

Temsirolimus

Back 51

Signal transduction inhibitors

Front 52

Eveolimus

Back 52

Signal transduction inhibitors

Front 53

Lapatinib

Back 53

Signal transduction inhibitors

Front 54

Tamoxifen

Back 54

Endocrine therapy

Front 55

Fulvestrant

Back 55

Endocrine therapy

Front 56

Toremifene

Back 56

Endocrine therapy

Front 57

Megestrol

Back 57

Endocrine therapy

Front 58

Anastrozole

Back 58

Endocrine therapy

Front 59

Aminoglutethimide

Back 59

Endocrine therapy

Front 60

Letrozole

Back 60

Endocrine therapy

Front 61

Exemestane

Back 61

Endocrine therapy

Front 62

Bicalutamide

Back 62

Endocrine therapy

Front 63

Flutamide

Back 63

Endocrine therapy

Front 64

Flutamide

Back 64

Endocrine therapy

Front 65

Leuprolide

Back 65

Endocrine therapy

Front 66

Goserelin

Back 66

Endocrine therapy

Front 67

a-interferon

Back 67

Biologic response modifiers

Front 68

Aldesleukin

Back 68

Biologic response modifiers

Front 69

Common adverse effects of this class are renal toxicity and N/V:

Back 69

DNA binding agents.

Front 70

Drugs in this class inhibit DNA synthesis in some way:

Back 70

Antimetabolites.

Front 71

Common adverse effects of this class are myelosuppression, mucositis, alopecia, and neuropathy:

Back 71

Antimetabolites.

Front 72

This drug may make the patient's tissues/fluids red:

Back 72

Doxorubicin.

Front 73

Converted to a much more potent metabolite, SN-38:

Back 73

Irinotecan.

Front 74

This mitotic inhibitor inhibits microtubule formation

Back 74

Vincristine.

Front 75

These mitotic inhibitors inhibit microtubule depolymerization:

Back 75

Paclitaxel and docetaxel.

Front 76

All signal transduction inhibitors undergo:

Back 76

CYP3A4 metabolism.

Front 77

Common features of this drug class are neuropathy and CYP3A4 metabolism:

Back 77

Mitotic inhibitors.

Front 78

Stimulates monocyte maturation into macrophages:

Back 78

a-interferon.

Front 79

Common adverse effects of DNA binding agents:

Back 79

N/V, nephrotoxicity.

Front 80

This antimetabolite inhibits DNA polymerase:

Back 80

Cytarabine.

Front 81

Elimination of this drug can be delayed of it is sequestered in an effusion:

Back 81

Methotrexate.

Front 82

Deficiency of DPD can lead to a lethal toxic level of:

Back 82

5-fluorouracil.

Front 83

Cyclosporin and paclitaxel inhibit clearance of:

Back 83

Doxorubicin.

Front 84

This class of drugs inhibits cells from entering mitosis:

Back 84

Topoisomerase I inhibs.

Front 85

This mitotic inhibitor causes SIADH, but does not cause myelosuppression:

Back 85

Vincristine.

Front 86

Common symptoms of this class are flu-like symptoms, CNS tox, and hepatotoxicity:

Back 86

Biologic response modifiers.

Front 87

The most widely prescribed drug in the US:

Back 87

Atorvastatin (Lipitor).

Front 88

Cholestyramine

Back 88

Bile acid binding product.

Front 89

Cholestipol

Back 89

Bile acid binding product.

Front 90

Ezetimibe

Back 90

Cholesterol absorption inhibitor.

Front 91

High levels of CEPT are correlated with:

Back 91

Low HDL.